Abstract:Enzymatic asymmetric sulfoxidation using molecular oxygen as the oxidant is a promising green chemistry approach to chiral sulfoxide production. Despite the broad substrate spectrum of cyclohexanone monooxygenases (CHMOs), some unnatural substrates with bulky functional groups, such as the pharmaceutically relevant omeprazole sulfide, cannot be effectively accepted by CHMOs. Herein, we describe a set of variants derived from an Acinetobacter calcoaceticus CHMO (AcCHMO), whose active sites adjacent to the substrate tunnel were altered to shift the substrate specificity from cyclohexanone monooxygenation toward omeprazole sulfide sulfoxidation. We performed homologous modeling and molecular docking to identify key residues that might affect the substrate specificity. Two libraries of residues lining the active center of AcCHMO were then constructed and screened by an effective halo-based selection method using the solubility difference between the substrate (omeprazole sulfide) and product (esomeprazole). Functional evaluation of the resultant variants showed that the substrate specificity of AcCHMO was markedly altered from the small natural substrate (cyclohexanone) toward the desired bulky substrate (omeprazole sulfide) despite the extremely poor activity detected even for the best variant, M2 (0.61 U/g(prot)). The crystal structure of M2 complexed with a flavin adenine dinucleotide (FAD) prosthetic group was determined, which provided insight into the altered substrate specificity. To improve the activity of enzyme M2 toward pharmaceutical precursor omeprazole sulfide, we performed both local and global protein engineering among the two CASTing libraries surrounding FAD(+) and NADP(+) prosthetic groups and an error-prone PCR library of the full-length AcCHMO. As a result, variant M6 was obtained, giving a 50-fold higher activity compared to M2. This structure-guided protein engineering of AcCHMO provided a promising candidate for converting omeprazole sulfide into (S)-omeprazole using a green biocatalytic method.

Engineered Cyclohexylamine Oxidase with Improved Activity and Stereoselectivity for Asymmetric Synthesis of a Bulky Dextromethorphan Precursor and Its Analogues

Asymmetric Synthesis of a Key Dextromethorphan Intermediate and Its Analogues Enabled by a New Cyclohexylamine Oxidase: Enzyme Discovery, Reaction Development, and Mechanistic Insight.

Improved Enantioselectivity of E. Coli BioH in Kinetic Resolution of Methyl (S)-3-cyclohexene-1-carboxylate by Combinatorial Modulation of Steric and Aromatic Interactions

Engineering of Cyclohexanone Monooxygenase for the Enantioselective Synthesis of (S)-Omeprazole

Engineered Imine Reductase for Asymmetric Synthesis of Dextromethorphan Key Intermediate

Semi-rational Engineering of Carbonyl Reductase YueD for Efficient Biosynthesis of Halogenated Alcohols with in Situ Cofactor Regeneration

Photoinduced Promiscuity of Cyclohexanone Monooxygenase for the Enantioselective Synthesis of Α‐fluoroketones

Enantiodivergent kinetic resolution of 4-substituted 1,2,3,4-tetrahydroquinolines employing amine oxidase

Protein engineering of thioether monooxygenase to improve its thermostability for enzymatic synthesis of chiral sulfoxide

Engineering an Epoxide Hydrolase for Chemoenzymatic Asymmetric Synthesis of Chiral Triazole Fungicide (S)- and (R)-Flutriafol

Reversal and Amplification of the Enantioselectivity of Biocatalytic Desymmetrization toward Meso Heterocyclic Dicarboxamides Enabled by Rational Engineering of Amidase

Customizing the Enantioselectivity of a Cyclohexanone Monooxygenase by a Strategy Combining “size‐probes” with in Silico Study

Photoinduced Promiscuity of Cyclohexanone Monooxygenase for the Enantioselective Synthesis of Α-Deuterated Carbonyl Compounds

An Engineered Imine Reductase for Highly Diastereo- and Enantioselective Synthesis of Β-Branched Amines with Contiguous Stereocenters

Engineering a Carbonyl Reductase as a Potential Tool for the Synthesis of Chiral α‐Tetralinols

Protein engineering of carbonyl reductase for asymmetric synthesis of ticagrelor precursor (1S)-2-chloro-1-(3,4-difluorophenyl)ethanol

Chemoenzymatic Approach to (s)‐1,2,3,4‐tetrahydroisoquinoline Carboxylic Acids Employing D‐Amino Acid Oxidase

Engineered Aldoxime Dehydratase to Enable the Chemoenzymatic Conversion of Benzyl Amines to Aromatic Nitriles

Sustainable Asymmetric Synthesis of Diltiazem Precursor Enabled by Recombinant Escherichia coli Whole Cells Co‐Expressing an Engineered Ketoreductase and Glucose Dehydrogenase

Engineered Imine Reductase Catalyzed Enantiodivergent Synthesis of Alkylated Amphetamines

Iridium-catalyzed enantioselective synthesis of chiral -amino alcohols and intermediates of (<i>S</i>)-duloxetine, (<i>R</i>)-fluoxetine, and (<i>R</i>)-atomoxetine